Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy
- 570 Downloads
Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer; however a technique that can accurately differentiate responders from non-responders at an early time point during treatment has still to be identified. The purpose of this work was to evaluate the ability of pharmacokinetically modelled dynamic contrast-enhanced MRI data to predict and monitor response of patients diagnosed with locally advanced breast cancer to neoadjuvant chemotherapy, at an early time point during treatment. Sixty-eight patients with histology proven breast cancer underwent MRI examination prior to treatment, early during treatment and following the final cycle of chemotherapy. A two compartment pharmacokinetic model provided the kinetic parameters transfer constant (Ktrans), rate constant (Kep) and extracellular extravascular space (Ve) for a region of interest encompassing the whole lesion (ROIwhole) and a 3 × 3 pixel ‘hot-spot’ showing the greatest mean maximum percentage enhancement from within that region (ROIhs). Following treatment 48 patients were classified as responders and 20 as non-responders based on total tumour volume reduction. Tumour volume changes between the pre-treatment and early treatment time points demonstrated differences between responders and non-responders with percentage change revealing the most significant result (p < 0.001). Analysis based on ROIhsprovided more statistically significant differences between responders and non-responders then ROIwhole analysis. ROIhs analysis demonstrated differences between responders and non-responders both prior to and early during treatment. A highly significant reduction in both Ktrans and Kep (p < 0.001) was noted for responders between the pre-treatment and early treatment time points, while Ve significantly increased during the same time period for non-responders (p < 0.001). Quantification of dynamic contrast enhancement parameters provides a potential means for differentiating responders from non-responders early during their treatment, thereby allowing a prompt change in treatment if necessary.
Keywordsbreast cancer Kep Ktrans neoadjuvant pharmacokinetic response Ve
Unable to display preview. Download preview PDF.
- 2.Kuerer, HM, Newman, LA, Buzdar, AU, Dhingra, K, Hunt, KK, Buchholz, TA, Binkley, SM, Strom, EA, Ames, FC, Ross, MI, Feig, BW, McNeese, , Hortobagyi, GN, Singletary, SE. 1998Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node statusCancer J Scientific Am4230236Google Scholar
- 15.Padhani AR, Hayes C, Assersohn L, Powles TJ, Leach MO, Husband JE: Response of breast carcinoma to chemotherapy – MR permeanbility changes using histogram analysis. Proceedings of the 8th International Society for Magnetic Resonance in Medicine. Denver, April 1–7 2000, p 2160Google Scholar
- 20.Ah-See MW, Taylor NJ, Makris A, Burcombe J, Stirling JJ, Cladd HJ, Leach MO, Padhani A: Preliminary evaluation of multi-functional MRI to predict response to neoadjuvant chemotherapy in primary breast cancer. American Society of Clinical Oncology 39th Annual Meeting, Chicago, 31 May-3 June 2003, p 556Google Scholar
- 21.Ah-See MW, Makris A, Taylor NJ, Harrison M, Richman P, Arcy JAD, Burcombe RJ, Pittam MR, Ravichandran D, Stirling JJ, Cladd HJ, Leach MO, Padhani AR: Multi-functional magnetic resonance imaging predicts for clinico-pathological response to neoadjuvant chemotherapy in primary breast cancer. 26th Annual San Antonio Breast Cancer Symposium, San Antonio, 3–6 December 2003, p 252Google Scholar
- 22.Galbraith, SM, Maxwell, RJ, Lodge, MA, Tozer, GM, Wilson, J, Taylor, NJ, Stirling, JJ, Sena, L, Padhani, AR, Rustin, GJS 2003Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingJ Clin Oncol2128312842CrossRefPubMedGoogle Scholar
- 23.Yamashita, Y, Baba, T, Baba, Y, Nishimura, R, Ikeda, S, Takahashi, M, Ohtake, H, Okamura, H 2000Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapyRadiology216803809PubMedGoogle Scholar
- 33.Su, MY, Cheung, YC, Fruehauf, JP, Yu, H, Nalcioglu, O, Mechetner, E, Kyshtoobayeva, A, Chen, SC, Hsueh, S, McLaren, CE, Wan, YL 2003Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancerJ Magn Reson Imaging18467477CrossRefPubMedGoogle Scholar
- 37.Tofts, PB. 2003Quantitative MRI of the BrainJohn Wiley & Sons LtdChichester341364Google Scholar